Fluvastatin improves osteoporosis in fructose-fed insulin resistant model rats through blockade of the classical mevalonate pathway and antioxidant action

International Journal of Molecular Medicine

Volumn 23, Issue 5, 2009, Pages 581-588

  Hanayama, Rie ^a   Shimizu, Hideo ^a   Nakagami, Hironori ^a   Osako, Mariana Kiomy ^a   Makino, Hirofumi ^a   Kunugiza, Yasuo ^a   Tomita, Tetsuya ^a   Tsukamoto, Ikuyo ^b   Yoshikawa, Hideki ^a   Rakugi, Hiromi ^a   Morishita, Ryuchi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NARA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Antioxidant; Osteoclast; Osteoporosis; Statins

Indexed keywords

ACETYLCYSTEINE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; COLONY STIMULATING FACTOR 1; DEOXYPYRIDINOLINE; DICHLORODIHYDROFLUORESCEIN; FARNESYL DIPHOSPHATE; FLUINDOSTATIN; FRUCTOSE; GERANYLGERANYL PYROPHOSPHATE; MEVALONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PRAVASTATIN; PYRROLIDINE DITHIOCARBAMATE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BONE DENSITY; CELL ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FRUCTOSE METABOLISM; INSULIN RESISTANCE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; OVARIECTOMY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STROMA CELL; WISTAR RAT;

ANIMALS; ANIMALS, NEWBORN; ANTIOXIDANTS; CELL DIFFERENTIATION; CELLS, CULTURED; DIET; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; FATTY ACIDS, MONOUNSATURATED; FEMALE; FRUCTOSE; INDOLES; INSULIN RESISTANCE; MEVALONIC ACID; OSTEOCLASTS; OSTEOPOROSIS; RABBITS; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 67649417908     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000167     Document Type: Article

References (28)

1. Rosen CJ and Bouxsein ML: Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2: 35-43, 2006.
2. McCabe LR: Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem 102: 1343-1357, 2007.
3. Basaria S: Link between diabetes and osteoporosis. Diabetes Care 23: 564-565, 2000.
4. Edwards CJ, Hart DJ and Spector TD: Oral statins and increased bone-mineral density in postmenopausal women. Lancet 355: 2218-2219, 2000.
5. Chan KA, Andrade SE, Boles M, et al: Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355: 2185-2188, 2000.
6. Wang PS, Solomon DH, Mogun H and Avorn J: HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283: 3211-3216, 2000.
7. Reid IR, Hague W, Emberson J, et al: Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 357: 509-512, 2001.
8. Van Staa TP, Wegman S, de Vries F, Leufkens B and Cooper C: Use of statins and risk of fractures. JAMA 285: 1850-1855, 2001.
9. Cappuccio FP, Kalaitzidis R, Duneclift S and Eastwood JB: Unravelling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism. J Nephrol 13: 169-177, 2000.
10. Resnick LM, Laragh JH, Sealey JE and Alderman MH: Divalent cations in essential hypertension. Relations between serum ionized calcium, magnesium, and plasma renin activity. N Engl J Med 309: 888-891, 1983.
11. Hwang IS, Ho H, Hoffman BB and Reaven GM: Fructose-induced insulin resistance and hypertension in rats. Hypertension 10: 512-516, 1987.
12. Suzumura K, Yasuhara M, Tanaka K, Odawara A, Narita H and Suzuki T: An in vitro study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor. Chem Pharm Bull 47: 1010-1012, 1999.
13. Venken K, Boonen S, Van Herck E, et al: Bone and muscle protective potential of the prostate-sparing synthetic androgen 7alpha-methyl-19-nortestosterone: evidence from the aged orchidectomized male rat model. Bone 36: 663-670, 2005.
14. Shimizu H, Sakamoto M and Sakamoto S: Bone resorption by isolated osteoclasts in living versus devitalized bone: differences in mode and extent and the effects of human recombinant tissue inhibitor of metalloproteinases. J Bone Miner Res 5: 411-418, 1990.
15. 2 for platelet-derived growth factor signal transduction. Science 270: 296-299, 1995.
16. Deng XF, Rokosh DG and Simpson PC: Autonomous and growth factor-induced hypertrophy in cultured neonatal mouse cardiac myocytes. Comparison with rat. Circ Res 87: 781-788, 2000.
17. Vanden Hoek TL, Becker LB, Shao Z, Li C and Schumacker PT: Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes. J Biol Chem 273: 18092-18098, 1998.
18. Shimizu H, Nakagami H, Tsukamoto I, et al: NFkappaB decoy oligodeoxynucleotides ameliorates osteoporosis through inhibition of activation and differentiation of osteoclasts. Gene Ther 13: 933-941, 2006.
19. Kunugiza Y, Tomita T, Tomita N, Morishita R and Yoshikawa H: Inhibitory effect of ribbon-type NF-kappaB decoy oligodeoxy-nucleotides on osteoclast induction and activity in vitro and in vivo. Arthritis Res Ther 8: R103, 2006.
20. Laufs U and Liao JK: Targeting Rho in cardiovascular disease. Circ Res 87: 526-528, 2000.
21. Shimizu H, Nakagami H, Osako MK, et al: Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 22: 2465-2475, 2008.
22. Mundy G, Garrett R, Harris S, et al: Stimulation of bone formation in vitro and in rodents by statins. Science 286: 1946-1949, 1999.
23. Maeda T, Matsunuma A, Kawane T and Horiuchi N: Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophy Res Commun 280: 874-877, 2001.
24. Ohnaka K, Shimoda S, Nawata H, et al: Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Bioch Biophy Res Commun 287: 337-342, 2001.
25. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC and Bellido T: Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104: 1363-1374, 1999.
26. Fisher JE, Rogers MJ, Halasy JM, et al: Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acade Sci USA 96: 133-138, 1999.
27. Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T and Fujita T: Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med 110: 584-587, 2001.
28. Tse FL, Jaffe JM and Troendle A: Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 32: 630-638, 1992.